Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
The greening of pharmaceutical engineering . Volume 1. : practice, analysis, and methodology / / M. R. Islam [and four others]
| The greening of pharmaceutical engineering . Volume 1. : practice, analysis, and methodology / / M. R. Islam [and four others] |
| Autore | Islam Rafiqul <1959-> |
| Pubbl/distr/stampa | Hoboken, New Jersey ; ; Salem, Massachusetts : , : Scrivener Publishing : , : Wiley, , 2015 |
| Descrizione fisica | 1 online resource (693 p.) |
| Disciplina | 615.1/9 |
| Collana | Wiley-Scrivener |
| Soggetto topico |
Pharmaceutical chemistry
Drugs - Analysis |
| ISBN |
1-119-18422-3
1-119-18420-7 1-119-18421-5 |
| Classificazione | TEC009010 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Half Title page; Title page; Copyright page; Preface; Chapter 1: Introduction; 1.1 Opening Remarks; 1.2 Are we Trained to Develop Contempt for Conscience and Addiction to Selfishness?; 1.3 Metadata; 1.4 Introducing Chapter Two: What's Behind Giving Up Honey and Promoting Aspartame as the Cure, i.e., Dumping the Natural Option in Favour of the Artificial One?; 1.5 Introducing Chapter Three: Are the Premises of New Science Sufficient for Uncovering or Establishing The Cause of Anything?; 1.6 Introducing Chapter Four: For How Long We Have Been Lied To?
1.7 Introducing Chapter Five: A Starting-Point for Society-Wide Corruption1.8 Introducing Chapter Six: Deconstruction of the Foundations of Aphenomenal Science in the Works of Newton (Part A) and Einstein (Part B); 1.9 Introducing Volume Two: The Way Out; 1.10 Introducing Chapter Seven: Concluding the Discussion-So-Far; 1.11 Introducing Chapter Eight: About the References and Bibliography, or: Now Previous Knowledge Can Help; Appendix 1.1; Appendix 1.2; Chapter 2: Current State of the World of Big Pharma; 2.1 Summary; 2.2 Introduction 4.3 Colony Collapse Disorder (CDC)4.4 Incurable Disease; 4.5 Diseases with Implications for Fundamental Theoretical Concerns (Mass, Energy and HTM); 4.6 The Need for the Science of Intangibles; 4.7 The Need for Studying the Time Dimension in Implicit Form; 4.8 Assessing the Overall Performance of a Process; 4.9 Aphenomenal Theories of Modern Era; 4.10 The Law of Conservation of Mass and Energy; 4.11 Toward Uncoverine Knowledge; 4.12 Conclusions; Chapter 5: Mass, Energy and Time: A Delinearized History; 5.1 Summary; 5.2 Introduction; 5.3 The Energy Crisis; 5.4 Gas Hydrates 5.5 Science of Healthy Energy and MassAppendix 5; Chapter 6: Newton & Einstein: A Delinearized Deconstruction; 6.1 Summary; 6.2 Introduction; 6.3 Historical Context; 6.4 Time Conceptions, Tangible-Intangible Nexus, and Social Roles of Knowledge; 6.5 What is New Versus what is Permitted: Science and the Establishment?; 6.6 Deconstruction of Einstein's Concept of Reality, Mass, Time, and Energy; 6.7 Conclusions; Chapter 7: The Nature-Science Approach: Conclusions of Book I; 7.1 Summary; 7.3 Struggle for Social Reform: Internal and External Factors 7.4 Consequences of Nature-Science for Classical Set Theory and Conventional Notions of Mensuration |
| Record Nr. | UNINA-9910137172603321 |
Islam Rafiqul <1959->
|
||
| Hoboken, New Jersey ; ; Salem, Massachusetts : , : Scrivener Publishing : , : Wiley, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The greening of pharmaceutical engineering . Volume 1. : practice, analysis, and methodology / / M. R. Islam [and four others]
| The greening of pharmaceutical engineering . Volume 1. : practice, analysis, and methodology / / M. R. Islam [and four others] |
| Autore | Islam Rafiqul <1959-> |
| Pubbl/distr/stampa | Hoboken, New Jersey ; ; Salem, Massachusetts : , : Scrivener Publishing : , : Wiley, , 2015 |
| Descrizione fisica | 1 online resource (693 p.) |
| Disciplina | 615.1/9 |
| Collana | Wiley-Scrivener |
| Soggetto topico |
Pharmaceutical chemistry
Drugs - Analysis |
| ISBN |
1-119-18422-3
1-119-18420-7 1-119-18421-5 |
| Classificazione | TEC009010 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Half Title page; Title page; Copyright page; Preface; Chapter 1: Introduction; 1.1 Opening Remarks; 1.2 Are we Trained to Develop Contempt for Conscience and Addiction to Selfishness?; 1.3 Metadata; 1.4 Introducing Chapter Two: What's Behind Giving Up Honey and Promoting Aspartame as the Cure, i.e., Dumping the Natural Option in Favour of the Artificial One?; 1.5 Introducing Chapter Three: Are the Premises of New Science Sufficient for Uncovering or Establishing The Cause of Anything?; 1.6 Introducing Chapter Four: For How Long We Have Been Lied To?
1.7 Introducing Chapter Five: A Starting-Point for Society-Wide Corruption1.8 Introducing Chapter Six: Deconstruction of the Foundations of Aphenomenal Science in the Works of Newton (Part A) and Einstein (Part B); 1.9 Introducing Volume Two: The Way Out; 1.10 Introducing Chapter Seven: Concluding the Discussion-So-Far; 1.11 Introducing Chapter Eight: About the References and Bibliography, or: Now Previous Knowledge Can Help; Appendix 1.1; Appendix 1.2; Chapter 2: Current State of the World of Big Pharma; 2.1 Summary; 2.2 Introduction 4.3 Colony Collapse Disorder (CDC)4.4 Incurable Disease; 4.5 Diseases with Implications for Fundamental Theoretical Concerns (Mass, Energy and HTM); 4.6 The Need for the Science of Intangibles; 4.7 The Need for Studying the Time Dimension in Implicit Form; 4.8 Assessing the Overall Performance of a Process; 4.9 Aphenomenal Theories of Modern Era; 4.10 The Law of Conservation of Mass and Energy; 4.11 Toward Uncoverine Knowledge; 4.12 Conclusions; Chapter 5: Mass, Energy and Time: A Delinearized History; 5.1 Summary; 5.2 Introduction; 5.3 The Energy Crisis; 5.4 Gas Hydrates 5.5 Science of Healthy Energy and MassAppendix 5; Chapter 6: Newton & Einstein: A Delinearized Deconstruction; 6.1 Summary; 6.2 Introduction; 6.3 Historical Context; 6.4 Time Conceptions, Tangible-Intangible Nexus, and Social Roles of Knowledge; 6.5 What is New Versus what is Permitted: Science and the Establishment?; 6.6 Deconstruction of Einstein's Concept of Reality, Mass, Time, and Energy; 6.7 Conclusions; Chapter 7: The Nature-Science Approach: Conclusions of Book I; 7.1 Summary; 7.3 Struggle for Social Reform: Internal and External Factors 7.4 Consequences of Nature-Science for Classical Set Theory and Conventional Notions of Mensuration |
| Record Nr. | UNINA-9910825304603321 |
|
Islam Rafiqul <1959->
|
||
| Hoboken, New Jersey ; ; Salem, Massachusetts : , : Scrivener Publishing : , : Wiley, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Guidance for industry [[electronic resource] ] : Q3A impurities in new drug substances
| Guidance for industry [[electronic resource] ] : Q3A impurities in new drug substances |
| Pubbl/distr/stampa | Sliver Spring, MD : , : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research |
| Descrizione fisica | 14 pages : digital, PDF file |
| Soggetto topico |
Drug adulteration
Drugs - Analysis Drug approval - United States |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Guidance for industry |
| Record Nr. | UNINA-9910698723303321 |
| Sliver Spring, MD : , : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Handbook of LC-MS bioanalysis : best practices, experimental protocols, and regulations / / edited by Wenkui Li, Jie Zhang, Francis L.S. Tse
| Handbook of LC-MS bioanalysis : best practices, experimental protocols, and regulations / / edited by Wenkui Li, Jie Zhang, Francis L.S. Tse |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, 2013 |
| Descrizione fisica | 1 online resource (706 p.) |
| Disciplina | 615.1/901 |
| Altri autori (Persone) |
LiWenkui <1964->
ZhangJie <1962-> TseFrancis L. S |
| Soggetto topico |
Drugs - Spectra
Drugs - Analysis Mass spectrometry Liquid chromatography |
| ISBN |
1-118-67135-X
1-118-67127-9 1-118-67134-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | pt. I. Overview of LC-MS bioanalysis -- pt. II. Current understanding of LC-MS bioanalysis-related regulations -- pt. III. Best practice in LC-MS bioanalysis -- pt. IV. Representative guidelines and/or experimental protocols of LC-MS bioanalysis. |
| Record Nr. | UNINA-9910139023203321 |
| Hoboken, N.J., : John Wiley & Sons, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Handbook of modern pharmaceutical analysis [[electronic resource] /] / edited by Satinder Ahuja, Stephen Scypinski
| Handbook of modern pharmaceutical analysis [[electronic resource] /] / edited by Satinder Ahuja, Stephen Scypinski |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Amsterdam, : Elsevier/Academic Press, 2011 |
| Descrizione fisica | 1 online resource (604 p.) |
| Disciplina | 615.1901 |
| Altri autori (Persone) |
AhujaSatinder <1933->
ScypinskiStephen |
| Collana | Separation science and technology |
| Soggetto topico |
Pharmaceutical chemistry
Drugs - Analysis |
| ISBN |
1-282-87902-2
9786612879029 0-12-375981-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Handbook of Modern Pharmaceutical Analysis; Copyright Page; Contents; Preface; Contributors; Chapter 1: overview of Modern pharmaceutical Analysis; I. Introduction; II. Solid-State Studies; III. Degradation and Impurities Studies; IV. Analytical Considerations for Genotoxic and Other Impurities; V. Quality by Design and Process Analytical Technology; VI. Novel Dosage Forms; VII. Method Development for Chiral Compounds; VIII. Characterization and Analysis of Biopharmaceutical Proteins; IX. Preformulation and Early Phase Method Development; X. In-Process Control Testing
XI. Method ValidationXII. Stability Studies; XIII. Method Transfer; XIV. Documentation; References; Chapter 2: Characterization of pharmaceutical Compounds in the Solid State; I. Introduction; II. Properties Associated with the Molecular Level; III. Properties Associated with the Particulate Level; IV. Properties Associated with the Bulk Level; V. Summary and Conclusions; References; Chapter 3: Degradation and Impurityanalysis for Pharmaceuticaldrug Candidates; I. Forced Degradation Studies; II. Isolation of Impurities/Degradants; III. Mass Spectrometry in the Identification of Impurities IV. NMRV. Case Studies; VI. Summary; References; Chapter 4: Analytical Considerations for Genotoxic and Other Impurities; I. Introduction; II. Concept of GTI Relative to Standard Impurities and the Current regulatory Thinking; III. Viracept® GTI Contamination Issue; IV. GTI Risk Assessment and Control Strategy Design; V. Analytical Challenges; VI. Summary and Conclusions; Acknowledgments; References; Chapter 5: Quality by Design and Theimportance of Pat in QbD; I. Introduction; II. The Role of Pat in QbD; III. Summary and Considerations Regarding Return on Investment for QbD/PAT; References Chapter 6: Novel Dosage form AnalysisI. Introduction; II. Tablets; III. Capsule Dosage Forms; IV. Cachet Dosage Forms; V. Sustained Release Dosage Forms; VI. Solution, Suspension, Emulsion, and Parenteral Dosage Forms; VII. Homogenization; VIII. Metered-Dose Inhalers; IX. Conclusions; References; Chapter 7: Method Development for Pharmaceutical Chiralchromatography; I. Introduction; II. Overview of Chiral Separations; III. Commercially Available Chiral Columns for Liquid Chromatography/Supercritical Fluid Chromatography; IV. Commercially Available Chiral Columns for GC V. Preparative Chiral chromatographyVI. Chiral Method Development Screening; VII. Chiral Detectors for LC/SFC Systems; VIII. Summary and Conclusions; References; Chapter 8: Characterization and Analysis of Biopharmaceutical Proteins; I. Introduction; II. Structure; III. Concentration; IV. Purity; V. Function; VI. Summary and Conclusions; Acknowledgments; References; Chapter 9: Preformulation and Early Phase Method Development; I. Introduction; II. Preformulation API Physicochemical Properties; III. Drug Product; IV. Clinical Dosage Forms; V. Conclusions; References Chapter 10: In-Process Control Testing |
| Record Nr. | UNINA-9910785124303321 |
| Amsterdam, : Elsevier/Academic Press, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Handbook of modern pharmaceutical analysis / / edited by Satinder Ahuja, Stephen Scypinski
| Handbook of modern pharmaceutical analysis / / edited by Satinder Ahuja, Stephen Scypinski |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Amsterdam, : Elsevier/Academic Press, 2011 |
| Descrizione fisica | 1 online resource (604 p.) |
| Disciplina | 615.1901 |
| Altri autori (Persone) |
AhujaSatinder <1933->
ScypinskiStephen |
| Collana | Separation science and technology |
| Soggetto topico |
Pharmaceutical chemistry
Drugs - Analysis |
| ISBN |
1-282-87902-2
9786612879029 0-12-375981-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Handbook of Modern Pharmaceutical Analysis; Copyright Page; Contents; Preface; Contributors; Chapter 1: overview of Modern pharmaceutical Analysis; I. Introduction; II. Solid-State Studies; III. Degradation and Impurities Studies; IV. Analytical Considerations for Genotoxic and Other Impurities; V. Quality by Design and Process Analytical Technology; VI. Novel Dosage Forms; VII. Method Development for Chiral Compounds; VIII. Characterization and Analysis of Biopharmaceutical Proteins; IX. Preformulation and Early Phase Method Development; X. In-Process Control Testing
XI. Method ValidationXII. Stability Studies; XIII. Method Transfer; XIV. Documentation; References; Chapter 2: Characterization of pharmaceutical Compounds in the Solid State; I. Introduction; II. Properties Associated with the Molecular Level; III. Properties Associated with the Particulate Level; IV. Properties Associated with the Bulk Level; V. Summary and Conclusions; References; Chapter 3: Degradation and Impurityanalysis for Pharmaceuticaldrug Candidates; I. Forced Degradation Studies; II. Isolation of Impurities/Degradants; III. Mass Spectrometry in the Identification of Impurities IV. NMRV. Case Studies; VI. Summary; References; Chapter 4: Analytical Considerations for Genotoxic and Other Impurities; I. Introduction; II. Concept of GTI Relative to Standard Impurities and the Current regulatory Thinking; III. Viracept® GTI Contamination Issue; IV. GTI Risk Assessment and Control Strategy Design; V. Analytical Challenges; VI. Summary and Conclusions; Acknowledgments; References; Chapter 5: Quality by Design and Theimportance of Pat in QbD; I. Introduction; II. The Role of Pat in QbD; III. Summary and Considerations Regarding Return on Investment for QbD/PAT; References Chapter 6: Novel Dosage form AnalysisI. Introduction; II. Tablets; III. Capsule Dosage Forms; IV. Cachet Dosage Forms; V. Sustained Release Dosage Forms; VI. Solution, Suspension, Emulsion, and Parenteral Dosage Forms; VII. Homogenization; VIII. Metered-Dose Inhalers; IX. Conclusions; References; Chapter 7: Method Development for Pharmaceutical Chiralchromatography; I. Introduction; II. Overview of Chiral Separations; III. Commercially Available Chiral Columns for Liquid Chromatography/Supercritical Fluid Chromatography; IV. Commercially Available Chiral Columns for GC V. Preparative Chiral chromatographyVI. Chiral Method Development Screening; VII. Chiral Detectors for LC/SFC Systems; VIII. Summary and Conclusions; References; Chapter 8: Characterization and Analysis of Biopharmaceutical Proteins; I. Introduction; II. Structure; III. Concentration; IV. Purity; V. Function; VI. Summary and Conclusions; Acknowledgments; References; Chapter 9: Preformulation and Early Phase Method Development; I. Introduction; II. Preformulation API Physicochemical Properties; III. Drug Product; IV. Clinical Dosage Forms; V. Conclusions; References Chapter 10: In-Process Control Testing |
| Record Nr. | UNINA-9910817296303321 |
| Amsterdam, : Elsevier/Academic Press, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
HPLC and UHPLC for practicing scientists / / Michael W. Dong
| HPLC and UHPLC for practicing scientists / / Michael W. Dong |
| Autore | Dong M. W. |
| Edizione | [Second edition.] |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley, , [2019] |
| Descrizione fisica | 1 online resource (411 pages) |
| Disciplina | 615.1901 |
| Soggetto topico |
High performance liquid chromatography
Drugs - Analysis |
| ISBN |
1-5231-2826-7
1-119-31379-1 1-119-31377-5 1-119-31378-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910554821903321 |
|
Dong M. W.
|
||
| Hoboken, New Jersey : , : Wiley, , [2019] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
HPLC and UHPLC for practicing scientists / / Michael W. Dong
| HPLC and UHPLC for practicing scientists / / Michael W. Dong |
| Autore | Dong M. W. |
| Edizione | [Second edition.] |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley, , [2019] |
| Descrizione fisica | 1 online resource (411 pages) |
| Disciplina | 615.1901 |
| Soggetto topico |
High performance liquid chromatography
Drugs - Analysis |
| ISBN |
1-5231-2826-7
1-119-31379-1 1-119-31377-5 1-119-31378-3 |
| Classificazione | SCI013010 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910831062703321 |
|
Dong M. W.
|
||
| Hoboken, New Jersey : , : Wiley, , [2019] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
HPLC for pharmaceutical scientists [[electronic resource] /] / edited by Yuri Kazakevich, Rosario LoBrutto
| HPLC for pharmaceutical scientists [[electronic resource] /] / edited by Yuri Kazakevich, Rosario LoBrutto |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley-Interscience, c2007 |
| Descrizione fisica | 1 online resource (1136 p.) |
| Disciplina |
615.19
615.1901 615/.1901 |
| Altri autori (Persone) |
KazakevichYuri
LoBruttoRosario |
| Soggetto topico |
High performance liquid chromatography
Drugs - Analysis Clinical chemistry |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-72166-9
9786610721665 0-470-08795-1 0-470-08794-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
HPLC FOR PHARMACEUTICAL SCIENTISTS; CONTENTS; PREFACE; CONTRIBUTORS; PART I HPLC THEORY AND PRACTICE; 1 Introduction; 1.1 Chromatography in the Pharmaceutical World; 1.2 Chromatographic Process; 1.3 Classification; 1.4 History of Discovery and Early Development (1903-1933); 1.5 General Separation Process; 1.5.1 Modern HPLC Column; 1.5.2 HPLC System; 1.6 Types of HPLC; 1.6.1 Normal-Phase Chromatography (NP HPLC); 1.6.2 Reversed-Phase HPLC (RP HPLC or RPLC); 1.6.3 Ion-Exchange Chromatography (IEX); 1.6.4 Size-Exclusion Chromatography (SEC); 1.7 HPLC Descriptors (Vr, k, N, etc.)
1.7.1 Retention Volume1.7.2 Void Volume; 1.7.3 Retention Factor; 1.7.4 Selectivity; 1.7.5 Efficiency; 1.7.6 Resolution; References; 2 HPLC Theory; 2.1 Introduction; 2.2 Basic Chromatographic Descriptors; 2.3 Efficiency; 2.4 Resolution; 2.5 HPLC Retention; 2.6 Retention Mechanism; 2.7 General Column Mass Balance; 2.8 Partitioning Model; 2.9 Adsorption Model; 2.10 Total and Excess Adsorption; 2.11 Mass Balance in Adsorption Model; 2.12 Adsorption of the Eluent Components; 2.13 Void Volume Considerations; 2.14 Thermodynamic Relationships; 2.14.1 Effect of the Eluent Composition 2.15 Adsorption-Partitioning Retention Mechanism2.16 Secondary Equilibria; 2.16.1 Inclusion of Secondary Equilibria in the Mass Balance; 2.16.2 Salt Effect; 2.17 Gradient Elution Principles; 2.18 Types of Analyte Interactions with the Stationary Phase; 2.19 Conclusion; References; 3 Stationary Phases; 3.1 Introduction; 3.2 Type of Packing Material (Porous, Nonporous, Monolithic); 3.3 Base Material (Silica, Zirconia, Alumina, Polymers); 3.4 Geometry; 3.4.1 Shape (Spherical/Irregular); 3.4.2 Particle Size Distribution; 3.4.3 Surface Area; 3.4.4 Pore Volume; 3.4.5 Surface Geometry 3.5 Adsorbent Surface Chemistry3.5.1 Surface Chemistry of the Base Material; 3.5.2 Silica; 3.5.3 Silica Hybrid; 3.5.4 Polymeric Packings; 3.5.5 Zirconia (Metal Oxides); 3.5.6 Porous Carbon (or Carbon-Coated Phases); 3.6 Surface of Chemically Modified Material; 3.6.1 Limits of Surface Modification; 3.6.2 Chemical Modification; 3.6.3 Types of Bonded Phases; 3.6.4 Structure of the Bonded Layer; 3.6.5 Density of Bonded Ligands; 3.6.6 Residual Silanoles; 3.6.7 Surface Area of Modified Adsorbent; 3.7 Polymer-Based Adsorbents; 3.8 Stationary Phases for Chiral Separations 3.8.1 Polysaccharide-Coated Phases3.8.2 Pirkle-Type Phases; 3.8.3 Protein Phases; 3.8.4 Molecular Imprinted Polymers for Chiral Separations; 3.9 Columns; 3.9.1 Capillary/Monolithic/Packed Columns; 3.9.2 Column Cleaning; 3.9.3 Column Void Volume; 3.9.4 Mass of Adsorbent in the Column; References; 4 Reversed-Phase HPLC; 4.1 Introduction; 4.2 Retention in Reversed-Phase HPLC; 4.3 Stationary Phases for RPLC; 4.4 Mobile Phases for RPLC; 4.4.1 Eluent Composition and Solvent Strength of the Mobile Phase; 4.4.2 Type of Organic Modifier 4.4.3 Selectivity as a Function of Type and Concentration of Organic Composition |
| Record Nr. | UNINA-9910143582603321 |
| Hoboken, N.J., : Wiley-Interscience, c2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
HPLC for pharmaceutical scientists [[electronic resource] /] / edited by Yuri Kazakevich, Rosario LoBrutto
| HPLC for pharmaceutical scientists [[electronic resource] /] / edited by Yuri Kazakevich, Rosario LoBrutto |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley-Interscience, c2007 |
| Descrizione fisica | 1 online resource (1136 p.) |
| Disciplina |
615.19
615.1901 615/.1901 |
| Altri autori (Persone) |
KazakevichYuri
LoBruttoRosario |
| Soggetto topico |
High performance liquid chromatography
Drugs - Analysis Clinical chemistry |
| ISBN |
1-280-72166-9
9786610721665 0-470-08795-1 0-470-08794-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
HPLC FOR PHARMACEUTICAL SCIENTISTS; CONTENTS; PREFACE; CONTRIBUTORS; PART I HPLC THEORY AND PRACTICE; 1 Introduction; 1.1 Chromatography in the Pharmaceutical World; 1.2 Chromatographic Process; 1.3 Classification; 1.4 History of Discovery and Early Development (1903-1933); 1.5 General Separation Process; 1.5.1 Modern HPLC Column; 1.5.2 HPLC System; 1.6 Types of HPLC; 1.6.1 Normal-Phase Chromatography (NP HPLC); 1.6.2 Reversed-Phase HPLC (RP HPLC or RPLC); 1.6.3 Ion-Exchange Chromatography (IEX); 1.6.4 Size-Exclusion Chromatography (SEC); 1.7 HPLC Descriptors (Vr, k, N, etc.)
1.7.1 Retention Volume1.7.2 Void Volume; 1.7.3 Retention Factor; 1.7.4 Selectivity; 1.7.5 Efficiency; 1.7.6 Resolution; References; 2 HPLC Theory; 2.1 Introduction; 2.2 Basic Chromatographic Descriptors; 2.3 Efficiency; 2.4 Resolution; 2.5 HPLC Retention; 2.6 Retention Mechanism; 2.7 General Column Mass Balance; 2.8 Partitioning Model; 2.9 Adsorption Model; 2.10 Total and Excess Adsorption; 2.11 Mass Balance in Adsorption Model; 2.12 Adsorption of the Eluent Components; 2.13 Void Volume Considerations; 2.14 Thermodynamic Relationships; 2.14.1 Effect of the Eluent Composition 2.15 Adsorption-Partitioning Retention Mechanism2.16 Secondary Equilibria; 2.16.1 Inclusion of Secondary Equilibria in the Mass Balance; 2.16.2 Salt Effect; 2.17 Gradient Elution Principles; 2.18 Types of Analyte Interactions with the Stationary Phase; 2.19 Conclusion; References; 3 Stationary Phases; 3.1 Introduction; 3.2 Type of Packing Material (Porous, Nonporous, Monolithic); 3.3 Base Material (Silica, Zirconia, Alumina, Polymers); 3.4 Geometry; 3.4.1 Shape (Spherical/Irregular); 3.4.2 Particle Size Distribution; 3.4.3 Surface Area; 3.4.4 Pore Volume; 3.4.5 Surface Geometry 3.5 Adsorbent Surface Chemistry3.5.1 Surface Chemistry of the Base Material; 3.5.2 Silica; 3.5.3 Silica Hybrid; 3.5.4 Polymeric Packings; 3.5.5 Zirconia (Metal Oxides); 3.5.6 Porous Carbon (or Carbon-Coated Phases); 3.6 Surface of Chemically Modified Material; 3.6.1 Limits of Surface Modification; 3.6.2 Chemical Modification; 3.6.3 Types of Bonded Phases; 3.6.4 Structure of the Bonded Layer; 3.6.5 Density of Bonded Ligands; 3.6.6 Residual Silanoles; 3.6.7 Surface Area of Modified Adsorbent; 3.7 Polymer-Based Adsorbents; 3.8 Stationary Phases for Chiral Separations 3.8.1 Polysaccharide-Coated Phases3.8.2 Pirkle-Type Phases; 3.8.3 Protein Phases; 3.8.4 Molecular Imprinted Polymers for Chiral Separations; 3.9 Columns; 3.9.1 Capillary/Monolithic/Packed Columns; 3.9.2 Column Cleaning; 3.9.3 Column Void Volume; 3.9.4 Mass of Adsorbent in the Column; References; 4 Reversed-Phase HPLC; 4.1 Introduction; 4.2 Retention in Reversed-Phase HPLC; 4.3 Stationary Phases for RPLC; 4.4 Mobile Phases for RPLC; 4.4.1 Eluent Composition and Solvent Strength of the Mobile Phase; 4.4.2 Type of Organic Modifier 4.4.3 Selectivity as a Function of Type and Concentration of Organic Composition |
| Record Nr. | UNINA-9910676633003321 |
| Hoboken, N.J., : Wiley-Interscience, c2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
